Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 26, 2025npj Precision OncologyOpen Access

SLC25A39 overexpression exacerbates lung adenocarcinoma progression and is negatively regulated by AFG3L2

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWenxuan HuJYJian YangZCZhike Chen

Discussion

Loading...

Member takes

Overview

Analysis reveals SLC25A39 as an oncogenic factor in lung adenocarcinoma, with AFG3L2 modulating its stability.

Key Points

  • SLC25A39 overexpression accelerates lung adenocarcinoma progression and correlates with poor patient outcomes.
  • Notably, elevated SLC25A39 protein levels are found despite stable mRNA expression in patients, suggesting post-translational regulation.
  • Knockdown of SLC25A39 suppresses lung adenocarcinoma cell proliferation and migration in various experimental models.
  • AFG3L2 downregulation enhances SLC25A39 stability, highlighting a potential therapeutic target in lung adenocarcinoma treatment.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/68d68f4ef2499b552fa25b32https://doi.org/10.1038/s41698-025-01081-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Upregulation of SLC25A1 by MAZ reprograms fatty acid synthesis and fuels LUAD malignancy.2025
  2. 2The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival2025
  3. 3Panoramic analysis of the biological function and clinical value of SLC38A2 in human cancers: a study based on pan-cancer and single-cell analysis2025
  4. 4SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia2025 · 4 citations
  5. 5Targeting FCRLA to induce necrosis in lung adenocarcinoma: a novel strategy for prognosis and therapy via MPT-Driven pathways2025